|Day Low/High||30.50 / 31.30|
|52 Wk Low/High||15.17 / 34.09|
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
The names include a veterinary drug concern plus companies with successful drugs on the market.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Pets can bring significant profits to companies that cater to this niche market.
Eli Lilly's excellent earnings weren't excellent enough.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
The limited technical data for the recent Eli Lilly spinoff indicate buyers came in early and appear to be holding.